Editas Medicine Inc. (NASDAQ:EDIT) went down by -4.75% from its latest closing price compared to the recent 1-year high of $99.95. The company’s stock price has collected -7.75% of loss in the last five trading sessions. Press Release reported 16 hours ago that Aadi Bioscience Appoints Emma Reeve to its Board of Directors
Is It Worth Investing in Editas Medicine Inc. (NASDAQ :EDIT) Right Now?
Plus, the 36-month beta value for EDIT is at 1.91. Opinions of the stock are interesting as 7 analysts out of 15 who provided ratings for Editas Medicine Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 4 rated it as “hold,” and 3 as “sell.”
The average price from analysts is $53.92, which is -$12.21 below the current price. EDIT currently public float of 66.83M and currently shorts hold a 10.13% ratio of that float. Today, the average trading volume of EDIT was 1.99M shares.
EDIT’s Market Performance
EDIT stocks went down by -7.75% for the week, with a monthly drop of -3.66% and a quarterly performance of 63.41%, while its annual performance rate touched 109.94%. The volatility ratio for the week stands at 6.60% while the volatility levels for the past 30 days are set at 7.14% for Editas Medicine Inc.. The simple moving average for the period of the last 20 days is -1.79% for EDIT stocks with a simple moving average of 26.22% for the last 200 days.
Analysts’ Opinion of EDIT
Many brokerage firms have already submitted their reports for EDIT stocks, with Oppenheimer repeating the rating for EDIT by listing it as a “Outperform.” The predicted price for EDIT in the upcoming period, according to Oppenheimer is $80 based on the research report published on September 10th of the current year 2021.
Truist, on the other hand, stated in their research note that they expect to see EDIT reach a price target of $80, previously predicting the price at $45. The rating they have provided for EDIT stocks is “Buy” according to the report published on August 09th, 2021.
Evercore ISI gave a rating of “Outperform” to EDIT, setting the target price at $60 in the report published on August 05th of the current year.
EDIT Trading at 16.25% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.01% of loss for the given period.
Volatility was left at 7.14%, however, over the last 30 days, the volatility rate increased by 6.60%, as shares surge +0.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.39% upper at present.
During the last 5 trading sessions, EDIT fell by -7.75%, which changed the moving average for the period of 200-days by +116.95% in comparison to the 20-day moving average, which settled at $64.12. In addition, Editas Medicine Inc. saw -10.20% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EDIT starting from ROBERTSON MICHELLE, who sale 2,500 shares at the price of $60.00 back on Aug 09. After this action, ROBERTSON MICHELLE now owns 28,735 shares of Editas Medicine Inc., valued at $150,000 using the latest closing price.
Hopfield Jessica, the Director of Editas Medicine Inc., purchase 5,800 shares at $45.51 during a trade that took place back on Mar 03, which means that Hopfield Jessica is holding 22,700 shares at $263,970 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -148.61 for the present operating margin
The net margin for Editas Medicine Inc. stands at -127.82. The total capital return value is set at -37.92, while invested capital returns managed to touch -33.20. Equity return is now at value -32.00, with -24.60 for asset returns.
Based on Editas Medicine Inc. (EDIT), the company’s capital structure generated 6.64 points at debt to equity in total, while total debt to capital is 6.23. Total debt to assets is 4.56, with long-term debt to equity ratio resting at 4.91. Finally, the long-term debt to capital ratio is 4.60.
When we switch over and look at the enterprise to sales, we see a ratio of 41.14, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 28.06 and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.20.